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BSTRACT
 
Background
 
Radiographic contrast agents can
cause a reduction in renal function that may be due
to reactive oxygen species. Whether the reduction
can be prevented by the administration of antioxi-
dants is unknown.
 
Methods
 
We prospectively studied 83 patients with
chronic renal insufficiency (mean [±SD] serum cre-
atinine concentration, 2.4±1.3 mg per deciliter [216±
116 µmol per liter]) who were undergoing computed
tomography with iopromide, a nonionic, low-osmolal-
ity contrast agent. Patients were randomly assigned
either to receive the antioxidant acetylcysteine (600
mg orally twice daily) and 0.45 percent saline intra-
venously, before and after administration of the con-
trast agent, or to receive placebo and saline.
 
Results
 
Ten of the 83 patients (12 percent) had an
increase of at least 0.5 mg per deciliter (44 µmol per
liter) in the serum creatinine concentration 48 hours
after administration of the contrast agent: 1 of the 41
patients in the acetylcysteine group (2 percent) and
9 of the 42 patients in the control group (21 percent;
P=0.01; relative risk, 0.1; 95 percent confidence inter-
val, 0.02 to 0.9). In the acetylcysteine group, the mean
serum creatinine concentration decreased significant-
ly (P<0.001), from 2.5±1.3 to 2.1±1.3 mg per deciliter
(220±118 to 186±112 µmol per liter) 48 hours after
the administration of the contrast medium, whereas
in the control group, the mean serum creatinine con-
centration increased nonsignificantly (P=0.18), from
2.4±1.3 to 2.6±1.5 mg per deciliter (212±114 to 226±
133 µmol per liter) (P<0.001 for the comparison be-
tween groups).
 
Conclusions
 
Prophylactic oral administration of the
antioxidant acetylcysteine, along with hydration, pre-
vents the reduction in renal function induced by io-
promide, a nonionic, low-osmolality contrast agent,
in patients with chronic renal insufficiency. (N Engl J
Med 2000;343:180-4.)
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DMINISTRATION of radiographic con-
trast agents often results in an acute re-
duction in renal function.
 
1-5
 
 The reduc-
tion can cause substantial morbidity and
mortality during hospitalization and can lead to
chronic end-stage renal disease.
 
1,5
 
 Important risk fac-
tors for contrast-agent–induced reductions in renal
function are preexisting renal dysfunction, particu-
larly that caused by diabetic nephropathy; reduced
effective arterial volume; concomitant administra-
tion of drugs that interfere with the regulation of re-
A
 
nal perfusion, such as angiotensin-converting–enzyme
inhibitors; and a higher volume of contrast agent ad-
ministered.
 
1,2,6
 
In patients with chronic renal insufficiency, hy-
dration has been reported to ameliorate contrast-
agent–induced reductions in renal function, but the
administration of drugs such as calcium antagonists,
theophylline, dopamine, and atrial natriuretic peptide
does not prevent the reduction.
 
5-12
 
 Contrast agents
reduce renal function by altering renal hemodynam-
ics and by exerting direct toxic effects on tubular ep-
ithelial cells. There is accumulating evidence that re-
active oxygen species have a role in the renal damage
caused by contrast agents.
 
13-15
 
 In rats, contrast agents
increased lipid peroxidation,
 
16
 
 and superoxide dis-
mutase, a scavenger of reactive oxygen species, pre-
served renal function.
 
14
 
On the assumption that reactive oxygen species
might be involved in the pathogenesis of acute con-
trast-agent–induced reductions in renal function, we
studied the effects of the prophylactic oral adminis-
tration of the antioxidant acetylcysteine in a prospec-
tive, placebo-controlled, randomized trial involving
patients with chronic renal insufficiency who were at
high risk for contrast-agent–induced renal damage.
 
METHODS
 
Patients
 
We prospectively studied 83 patients with a serum creatinine
concentration above 1.2 mg per deciliter (106 µmol per liter) or
creatinine clearance of less than 50 ml per minute (0.8 ml per sec-
ond). Creatinine clearance was estimated on the basis of the se-
rum creatinine concentration, weight, age, and sex.
 
17
 
 Only pa-
tients known to have a history of chronic renal failure and with
stable serum creatinine concentrations were included. Repeated
measurements during the week before the administration of the
contrast agent revealed only minor changes in serum creatinine
concentrations (mean [±SD] variation, 0.1±0.3 mg per deciliter
[9±26 µmol per liter]; P=0.12). No patient with acute renal fail-
ure was included. The cause of renal insufficiency was diabetic ne-
phropathy in 27 patients, nephrosclerosis in 20 patients, glomer-
ulonephritis in 12 patients, tubulointerstitial nephritis in 4 patients,
and unknown in 20 patients. All the patients underwent elective
computed tomography (CT) with a nonionic low-osmolality ra-
diographic contrast agent. The indications for CT were deter-
mined by each patient’s physician. Most patients underwent CT
for the evaluation of an abdominal or thoracic illness. 
The New England Journal of Medicine 
Downloaded from nejm.org on January 16, 2017. For personal use only. No other uses without permission. 
 Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
 PREVENTION OF RADIOGRAPHIC-CONTRAST-AGENT–INDUCED REDUCTIONS IN RENAL FUNCTION BY ACETYLCYSTEINE
 
Volume 343 Number 3
 
·
 
181
 
The study protocol was approved by the local ethics commit-
tee, and all patients gave written informed consent.
 
Study Protocol
 
The patients were randomly assigned to receive either the an-
tioxidant acetylcysteine and intravenous saline before and after
administration of the contrast agent (acetylcysteine group) or pla-
cebo and saline (control group). Acetylcysteine was given orally
at a dose of 600 mg twice daily, on the day before and on the
day of administration of the contrast agent, for a total of two
days. Saline (0.45 percent) was given intravenously at a rate of
1 ml per kilogram of body weight per hour for 12 hours before
and 12 hours after administration of the contrast agent. All pa-
tients were encouraged to drink if they were thirsty. The dose of
nonionic, low-osmolality contrast agent (iopromide; Ultravist-300,
Schering, Berlin, Germany) was 75 ml for all patients. The infu-
sion contained 0.623 g of iopromide per milliliter, and the iodine
content was 300 mg per milliliter. None of the patients received
theophylline, dopamine, mannitol, or furosemide during the study.
Serum creatinine and urea nitrogen were measured repeatedly
during the week before administration of the contrast agent, as
noted above, and immediately before, 48 hours after, and 6 days
after administration of the contrast agent. An acute contrast-
agent–induced reduction in renal function was defined as an in-
crease in the serum creatinine concentration of at least 0.5 mg
per deciliter (44 µmol per liter) 48 hours after administration of
the contrast agent.
Acetylcysteine (final concentration, 2.5 mmol per liter) was
added in vitro to serum samples from the patients, and serum cre-
atinine was measured. In the presence of acetylcysteine, the mean
serum creatinine concentration was 100±1 percent of the serum
creatinine concentration in the absence of acetylcysteine.
 
Statistical Analysis
 
The final analysis was conducted on an intention-to-treat basis.
Categorical variables (e.g., the incidence of acute contrast-agent–
induced reductions in renal function) were analyzed by Fisher’s
exact test. Differences between the groups in serum creatinine
concentrations were analyzed by the nonparametric Wilcoxon–
Mann–Whitney test. A multiple logistic-regression analysis was
used to examine the effect of acetylcysteine, with adjustment for
base-line blood pressure. The logistic-regression analysis was per-
formed with the acute contrast-agent–induced reduction in renal
function as the dependent variable. Analyses were performed with
GraphPad Prism software (version 3.0, GraphPad Software, San
Diego, Calif.), or SPSS software (release 8.0.0, SPSS, Chicago).
All statistical tests were two-sided.
 
RESULTS
 
The clinical and biochemical characteristics of the
patients are shown in Table 1. The mean weights of
the patients were similar at the start of the study (con-
trol group, 76±13 kg; acetylcysteine group, 77±12
kg) and at the end (control group, 77±13 kg; ace-
tylcysteine group, 78±12 kg), suggesting a similar
fluid balance.
The mean serum creatinine concentration for all
patients was 2.4±1.3 mg per deciliter (216±116 µmol
per liter). In the control group, the mean serum cre-
atinine concentration increased from 2.4±1.3 to 2.6±
1.5 mg per deciliter (212±114 to 226±133 µmol
per liter) 48 hours after administration of the con-
trast agent (P=0.18) (Fig. 1). In the acetylcysteine
group, the mean serum creatinine concentration de-
creased from 2.5±1.3 to 2.1±1.3 mg per deciliter
(220±118 to 186±112 µmol per liter) 48 hours af-
ter administration of the contrast agent (P<0.001).
The absolute change in serum creatinine concentra-
tion was significantly greater in the control group
than in the acetylcysteine group (P<0.001) (Table 2).
In the control group, the mean serum urea nitro-
gen concentration was 44±26 mg per deciliter (15±9
mmol per liter) before and 47±29 mg per deciliter
(17±10 mmol per liter) 48 hours after administra-
tion of the contrast agent (P=0.38). In the acetyl-
cysteine group, the mean serum urea nitrogen con-
centration significantly decreased from 51±28 mg per
deciliter (18±10 mmol per liter) before to 44±29
mg per deciliter (16±10 mmol per liter) 48 hours
after administration of the contrast agent (P<0.001).
An acute contrast-agent–induced reduction in re-
nal function was defined as an increase in the serum
creatinine concentration of at least 0.5 mg per dec-
iliter (44 µmol per liter) 48 hours after administra-
tion of the contrast agent. Such an increase occurred
in 10 of the 83 patients (12 percent): 1 of the 41
patients in the acetylcysteine group (2 percent) and
9 of the 42 patients in the control group (21 per-
cent; P=0.01; relative risk, 0.1; 95 percent confi-
dence interval, 0.02 to 0.9). Base-line systolic and
diastolic blood pressure did not influence the find-
ings. Five of the 10 patients with an acute contrast-
agent–induced reduction in renal function had dia-
betes mellitus.
In the acetylcysteine group, 13 patients (32 per-
cent) had base-line serum creatinine concentrations
above 2.5 mg per deciliter (221 µmol per liter), as
did 12 patients (29 percent) in the control group.
Among these patients with elevated base-line creati-
nine concentrations, none of the 13 patients in the
acetylcysteine group and 5 of the 12 patients in the
 
*Plus–minus values are means ±SD. To convert values for serum creat-
inine to micromoles per liter, multiply by 88.4. Body-mass index was cal-
culated as the weight in kilograms divided by the square of the height in
meters. There were no significant differences between the groups (P>0.05
for all comparisons).
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G
 
ROUP
 
 (N=41)
C
 
ONTROL
 
 
G
 
ROUP
 
 (N=42)
 
Age — yr 66±11 65±15
Sex — M/F 24/17 23/19
Body-mass index 27.1±4.3 26.4±4.7
Blood pressure — mm Hg 139/79±18/10 141/77±24/12
Serum creatinine — mg/dl 2.5±1.3 2.4±1.3
Diabetes mellitus — no. (%) 13 (32) 14 (33)
Diuretic therapy — no. (%) 28 (68) 24 (57)
Calcium-channel blocker — no. (%) 8 (20) 5 (12)
Angiotensin-converting–enzyme 
inhibitor — no. (%)
8 (20) 6 (14)
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control group (42 percent) had an acute contrast-
agent–induced reduction in renal function (P=0.02).
Among the patients with an acute contrast-agent–
induced reduction in renal function, the mean se-
rum creatinine concentration was still elevated on
day 6 after the administration of the contrast agent
(by 0.5±0.6 mg per deciliter [43±50 µmol per li-
ter] over base line). None of the patients required
dialysis. Three of the 41 patients in the acetylcys-
teine group (7 percent) and 5 of the 42 patients in
the control group (12 percent) reported temporary
gastrointestinal discomfort during the study; 4 pa-
tients in the acetylcysteine group (10 percent) and
3 patients in the control group (7 percent) reported
dizziness. There were no other adverse effects.
 
DISCUSSION
 
The important finding of this study is that prophy-
lactic oral administration of the antioxidant acetylcys-
teine reduced the incidence of acute contrast-agent–
induced reductions in renal function. In addition,
the absolute change in the serum creatinine concen-
tration after administration of the contrast agent was
less in the acetylcysteine group than in the control
group. The results were similar in the subgroup of
patients with initial serum creatinine concentrations
above 2.5 mg per deciliter. To exclude the possibility
that the effects of acetylcysteine were due only to a
 
Figure 1.
 
 Serum Creatinine Concentrations before and 48 Hours after the Administration of Contrast
Agent to Patients with Chronic Renal Insufficiency.
Mean (±SD) concentrations for the acetylcysteine group (41 patients) and for the control group (42
patients) are indicated by squares and vertical lines. To convert values for serum creatinine to micro-
moles per liter, multiply by 88.4.
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*Plus–minus values are means ±SD. To convert values for serum creat-
inine to micromoles per liter, multiply by 88.4. Mean serum creatinine con-
centrations decreased significantly (P<0.001) in the acetylcysteine group
and increased nonsignificantly (P=0.18) in the control group.
†The Wilcoxon–Mann–Whitney test was used for the comparison be-
tween the groups.
‡Fisher’s exact test was used for the comparison between the groups.
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Serum creatinine concentra-
tion — mg/dl 
Base line
Change 48 hr after adminis-
tration of contrast agent
2.5±1.3
¡0.4±0.4
2.4±1.3
+0.2±0.6
0.55
<0.001†
Incidence of acute reductions in
renal function — no. (%)
1 (2) 9 (21) 0.01‡
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direct effect on the tubular secretion of creatinine,
with renal function left unaffected, we also measured
serum urea nitrogen. The changes in serum urea ni-
trogen concentrations were similar to those in serum
creatinine concentrations, suggesting that changes in
glomerular filtration may underlie the observed chang-
es in serum creatinine concentrations.
The incidence of acute contrast-agent–induced re-
ductions in renal function varies from 0 to 90 per-
cent, depending on the presence of risk factors, in-
cluding chronic renal insufficiency, diabetes mellitus,
and a higher volume of contrast agent administered.
 
1-8
 
The incidence of acute contrast-agent–induced reduc-
tions in renal function among patients with diabetes
has been reported to be 9 to 40 percent in patients
with mild-to-moderate chronic renal insufficiency
and 50 to 90 percent in patients with severe chronic
renal insufficiency.
 
1,2
 
 The present study included di-
abetic as well as nondiabetic patients with chronic
renal insufficiency, since diabetic patients are thought
to be at high risk for contrast-agent–induced reduc-
tions in renal function.
As recommended in earlier studies, we defined an
acute contrast-agent–induced reduction in renal func-
tion as an increase in the serum creatinine concen-
tration of at least 0.5 mg per deciliter 48 hours after
administration of the contrast agent.
 
1-8
 
 Such an in-
crease may be important, because it can increase the
duration of hospitalization.
 
5
 
 To avoid any bias due
to the use of different types of contrast agent or the
administration of different volumes, 75 ml of the
same nonionic, low-osmolality contrast agent was giv-
en to all the patients. The use of such agents is as-
sociated with a lower incidence of acute reductions
in renal function than the use of ionic, high-osmo-
lality agents.
 
6,18
 
 Earlier studies support the use of hy-
dration in patients with chronic renal insufficiency
to prevent acute contrast-agent–induced reductions
in renal function.
 
4-8
 
How can the beneficial effect of acetylcysteine be
explained? Contrast-agent–induced reductions in re-
nal function are due to alterations in renal hemody-
namics and direct toxic effects on tubular epithelial
cells. The toxic renal damage may contribute to the
formation of reactive oxygen species or to reduced
antioxidant activity.
 
13-15
 
 Recent studies suggest that
acetylcysteine has vasodilatory properties.
 
19,20
 
 In an-
imals, acetylcysteine can ameliorate ischemic renal
failure,
 
21,22
 
 and it has been reported to block the ex-
pression of vascular-cell adhesion molecule 1 and the
activation of nuclear factor-
 
k
 
B in glomerular mesan-
gial cells.
 
23
 
 Early administration of acetylcysteine pre-
vents a reduction in renal function in patients with
acetaminophen poisoning who have liver failure.
 
24,25
 
A recent nonrandomized study suggested that ace-
tylcysteine may improve renal function in patients
with the hepatorenal syndrome.
 
26
 
 Therefore, it may
be capable of preventing a contrast-agent–induced
reduction in renal function both by improving renal
hemodynamics and by preventing direct oxidative
tissue damage.
In conclusion, prophylactic oral administration of
the antioxidant acetylcysteine at a dose of 600 mg
twice daily on the day before and on the day of ad-
ministration of the contrast agent, together with hy-
dration with saline, is an effective means of preventing
renal damage induced by a nonionic, low-osmolality
contrast agent in patients with chronic renal insuffi-
ciency.
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